Related Experiment Video

Updated: Sep 27, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

[Single nucleotide polymorphism and novel drug discovery]

Ryuichi Kato1

  • 1School of Medicine, Keio University.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 4, 2003
PubMed

Insights

Identifying genetic polymorphisms offers therapeutic targets for diseases. Gene examination in clinical trials helps classify patient responses to targeted drugs, optimizing treatment outcomes.

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Drug Development

Background:

  • Genetic polymorphisms significantly influence drug response and disease susceptibility.
  • Understanding these variations is crucial for personalized medicine.
  • Current drug development lacks comprehensive integration of genetic factors.

Purpose of the Study:

  • To highlight the role of genetic polymorphisms in identifying therapeutic targets.
  • To emphasize the necessity of gene examination in clinical trials for patient stratification.
  • To underscore the impact of genetic variations on drug pharmacokinetics, metabolism, efficacy, and toxicity.

Main Methods:

  • Review of existing literature on genetic polymorphisms and drug response.
  • Analysis of the implications of genetic variations in drug development pipelines.
  • Case study examples illustrating the impact of pharmacogenomics in clinical trials.

Main Results:

  • Genetic polymorphisms can serve as biomarkers for predicting drug efficacy and toxicity.
  • Gene examination allows for the classification of patients into responders and non-responders.
  • Pharmacokinetic and metabolic profiles are demonstrably altered by specific genetic variations.

Conclusions:

  • Genetic polymorphism research is essential for discovering novel therapeutic targets.
  • Integrating gene examination into clinical trials enhances drug development efficiency and patient safety.
  • Pharmacogenomic insights are critical for optimizing drug selection and minimizing adverse events.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

The Visual Colorimetric Detection of Multi-nucleotide Polymorphisms on a Pneumatic Droplet Manipulation Platform10:01

The Visual Colorimetric Detection of Multi-nucleotide Polymorphisms on a Pneumatic Droplet Manipulation Platform

Published on: September 27, 2016

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...